clinical trial · NCT07823127
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)
Intrahepatic Cholestasis of PregnancyMaralixibat
brief summary
This study is designed to assess whether the investigational drug maralixibat, is safe and well tolerated in pregnant women with intrahepatic cholestasis of pregnancy (ICP). This is an open-label study where all participants will receive maralixibat.
started
Jan 15, 2027
primary completion
Jan 12, 2029
completion
Jan 12, 2029
last updated
Sep 16, 2026
official title
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) (OASIS)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol